Independent meta-analysis of head-to-head drug-eluting stent trials shows differences in rates of re-treatment (TLR) and restenosis
WASHINGTON, D.C. – (October 20, 2005) – The most comprehensive and detailed analysis conducted to date of drug-eluting stent comparative trials shows a marked difference in the rate of target lesion revascularization (TLR) and restenosis in patients who received the CYPHER® Stent vs. the Taxus Stent in seven studies totaling 4,214 patients. The CYPHER® Stent vs. Taxus Stent meta-analysis was presented today to cardiologists and other attendees from throughout the world during the Cardiovascular Research Foundation's (CRF) 17th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
The purpose of this meta-analysis was to systematically review randomized comparative DES trials and obtain a more precise understanding of the true treatment effect of the CYPHER® Stent and the Taxus Stent than any individual trial can provide.
Stephan Winndecker, M.D. and Peter Juni, M.D. of University Hospital Bern in Switzerland conducted a thorough review of clinical results from the head-to-head trials, analyzed extended patient follow-up data and initiated an extensive review of publications and information on these trials, many of which have been published in major medical journals.
The meta-analysis of the seven head-to-head drug-eluting stent trials – TAXI, SIRTAX, ISAR DESIRE, ISAR DIABETES, REALITY, CORPAL and BASKET - demonstrated that the CYPHER® Stent more effectively reduced the need for re-treatment, target lesion revascularization, by about 30% compared to Taxus Stent-treated patients.
"The benefit of the CYPHER® Stent in reducing the need for re-treatment was observed in multiple patient and lesion types in this analysis," stated Dennis Donohoe, M.D., vice president of worldwide clinical research and regulatory affairs for Cordis Corporation. "This rigorously conducted meta analysis establishes the highest level of scientific evidence of the relative performance of these two drug-eluting stents. The CYPHER® Stent's strong clinical performance across these trials is clearly demonstrated and will be of great value to physicians and patients.
The data from the seven trials studied in this analysis have been previously presented in medical congresses or published in journals:
Trial: Follow-up at time of analysis: Presented/Published: BASKET 6 months Lancet 2005 CORPAL 13 months ACC 2005, submitted for publication ISAR-DESIRE 12 months JAMA 2005 ISAR-DIABETES 9 months NEJM 2005 REALITY 9 months ACC 2005, submitted for publication SIRTAX 12 months NEJM 2005 TAXI 12 months JACC 2005
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
The best way out is always through.
-- Robert Frost